The overpassaged cells might present distinct characteristics from their original cancer tissues and generate erroneous results.25 Thus, in order to deliver more clinically relevant results, we investigated if and how pharmaceutical-grade IgG affects the anti-carcinoma activity of oxaliplatin in colon cancer cells using a series of novel patient-derived colon cancer cell lines.26 In addition, we evaluated if the ERK1/2 signal transduction pathway was involved in the interactions between IgG and oxaliplatin. The gene discussed is MAPK3; the disease is cancer.